Targeting HMGB1 and Its Interaction with Receptors: Challenges and Future Directions
Journal of Medicinal Chemistry · 26.12.2024 · 67 (24) · 21671-21694
DOI: 10.1021/acs.jmedchem.4c01912 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 09.12.2024. Verfasst von Pingping Shen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Resources Science of Traditional Chinese Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 21…. Hauptthemen laut MEDLINE: HMGB1 Protein. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 226 Literaturangaben. Gefördert von: Program for New Century Excellent Talents in University, National Natural Science Foundation of China, Jiangsu Funding Program for Excellent Postdoctoral Talent.
Abstract (Originalsprache)
High mobility group box 1 (HMGB1) is a nonhistone chromatin protein predominantly located in the nucleus. However, under pathological conditions, HMGB1 can translocate from the nucleus to the cytoplasm and subsequently be released into the extracellular space through both active secretion and passive release mechanisms. The distinct cellular locations of HMGB1 facilitate its interaction with various endogenous and exogenous factors, allowing it to perform diverse functions across a range of diseases. This Perspective provides a comprehensive overview of the structure, release mechanisms, and multifaceted roles of HMGB1 in disease contexts. Furthermore, it introduces the development of both small molecule and macromolecule inhibitors targeting HMGB1 and its interaction with receptors. A detailed analysis of the predicted pockets is also presented, aiming to establish a foundation for the future design and development of HMGB1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Resources Science of Traditional Chinese Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, P. R. China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China.
- Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, P. R. China.
ORCID-Profile: Jian Zhang
Förderung
- Program for New Century Excellent Talents in University
- National Natural Science Foundation of China
- Jiangsu Funding Program for Excellent Postdoctoral Talent
Zitieren
APA
Shen, P., Zhang, L., Jiang, X., Yu, B., & Zhang, J. (2024). Targeting HMGB1 and Its Interaction with Receptors: Challenges and Future Directions. Journal of Medicinal Chemistry, 67(24), 21671-21694. https://doi.org/10.1021/acs.jmedchem.4c01912
Vancouver
Shen P, Zhang L, Jiang X, Yu B, Zhang J. Targeting HMGB1 and Its Interaction with Receptors: Challenges and Future Directions. Journal of Medicinal Chemistry. 2024;67(24):21671-21694. doi:10.1021/acs.jmedchem.4c01912
BibTeX
@article{Shen2024,
author = {Shen, Pingping and Zhang, Libang and Jiang, Xuewa and Yu, Boyang and Zhang, Jian},
title = {Targeting HMGB1 and Its Interaction with Receptors: Challenges and Future Directions},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {24},
pages = {21671--21694},
doi = {10.1021/acs.jmedchem.4c01912}
}
EUVIMED